| 胡丹丹,李文娟,金伟,等.卡瑞利珠单抗治疗晚期肝癌58例[J].中国临床保健杂志,2022,25(6):833-836. |
| 卡瑞利珠单抗治疗晚期肝癌58例 |
| Treatment of 58 cases of advanced liver cancer with carelizumab |
| 投稿时间：2022-10-17 |
| DOI：10.3969/J.issn.1672-6790.2022.06.025 |
| 中文关键词: 肝肿瘤 药物相关性副作用和不良反应 治疗结果 无进展生存期 预后 |
| 英文关键词: Liver neoplasms Drug-related side effects and adverse reactions Treatment outcome Progression-free survival Prognosis 〖FL |
| 基金项目:安徽省医疗卫生重点专科肿瘤生物治疗科资金支持项目(2021sjlczdzk)；中国科学技术大学新医学联合基金项目(WK9110000010) |
|
| 摘要点击次数: 1349 |
| 全文下载次数: 2151 |
| 中文摘要: |
| 目的 探讨卡瑞利珠单抗治疗晚期肝癌的效果。方法 纳入2018年1月至2021年12月在安徽省肿瘤医院使用卡瑞利珠单抗治疗的晚期肝细胞癌和肝内胆管细胞癌共58例。分析卡瑞利珠单抗治疗肝癌的疗效和治疗产生的免疫相关不良反应以及两者之间的相关性。结果 2周期疾病控制率(DCR)为89.7%,中位无进展生存期(mPFS)为8.4个月。39例患者发生免疫相关不良反应(irAEs),免疫相关不良反应总体发生率为67.2%,其中轻度irAEs(1~2级)有36例,重度irAEs(3~4级)有3例。只发生1种irAEs有24例,发生2种及以上irAEs有15例。发生irAEs组mPFS较未发生irAEs组延长(9.5个月比6.5个月)。发生2种及以上irAEs组的mPFS较只发生1种irAEs组的mPFS进一步延长(10.5个月比8.4个月)。结论 卡瑞利珠单抗治疗晚期肝癌疗效较好,免疫相关不良反应可控,且发生免疫相关不良反应者预后较好。 |
| 英文摘要: |
| Objective To explore the effect of camrelizumab in the treatment of advanced liver cancer.Methods A total of 58 patients with advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma who were treated with camrelizumab in Anhui Cancer Hospital from January 2018 to December 2021 were included in this study.The efficacy and immune-related adverse reactions of camrelizumab in the treatment of liver cancer were analyzed.Results The 2-cycle disease control rate (DCR) was 89.7%,and the mPFS was 8.4 months.Immune-related adverse reactions (irAEs) occurred in 39 cases,The overall incidence of irAEs during treatment was 67.2%,of which 36 were mild (grade 1-2) and 3 were severe (grade 3-4).24 cases had only one irAEs,and 15 cases had two or more irAEs.The median mPFS in the treatment group with immune-related adverse reactions was prolonged compared with the group without (9.5 vs.6.5 months).The mPFS of patients with two or more irAEs was further prolonged than that of patients with only one irAEs (10.5 vs.8.4 months).Conclusions Camrelizumab has good efficacy in the treatment of advanced liver cancer,immune-related adverse reactions are controllable,and the patients with immune-related adverse reactions has a better prognosis. |
|
查看全文
|
| 关闭 |
|
|
|